With multiple autologous CAR-T cell therapies approved and showing high levels of clinical activity against leukemias, lymphomas and multiple myeloma, an increasingly important arena of competition now is not just efficacy, but vein-to-vein time – how quickly sponsors can take patients’ T-cells, manufacture the CAR-T and get the finished product back to them. Bristol Myers Squibb Company’s partnership with Cellares is aimed at increasing its competitiveness in that regard.
The two companies announced 22 April a deal in which BMS will pay Cellares $380m in upfront and milestone payments for a capacity reservation and supply agreement to manufacture BMS’s...
Key Takeaways
-
BMS signed a $380m deal with Cellares to manufacture an undisclosed number of CAR-T therapies at factories in the US, EU and Japan.
- ...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
